Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY News - neoadjuvant therapy

MedXY AI/MedXY News/Tag: neoadjuvant therapy

MedXY News

EnglishTag

neoadjuvant therapy

23 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk biomarkers Cardiology clinical trials critical care Hypertension oncology public health artificial intelligence Alzheimer's disease breast cancer diabetes type 1 diabetes cardiovascular disease chronic kidney disease nutrition

Latest news

Tag

Combining Anatomical and Histologic Response Predicts Recurrence After Surgery for Colorectal Liver Metastases

Oncologycolorectal liver metastasesneoadjuvant therapy

Combining Anatomical and Histologic Response Predicts Recurrence After Surgery for Colorectal Liver Metastases

By MedXY|Jul 29, 2026

A multi-institutional study of 483 patients shows that combining macroscopic (TBSr) and histologic (TRG) response to neoadjuvant therapy better stratifies recurrence risk after hepatectomy for colorectal liver metastases than either measure alone.

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

circulating tumor DNA

ctDNA

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

By MedXY|Jun 28, 2026

The DAPHNe trial demonstrates excellent 5-year outcomes for stage II–III ERBB2-positive breast cancer patients treated with an abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen, with ultrasensitive ctDNA monitoring sho

Redefining Success in Neoadjuvant Therapy for Pancreatic Cancer: The Prognostic Significance of Major Pathologic Response

Clinical Updatesneoadjuvant therapyPancreatic Cancer

Redefining Success in Neoadjuvant Therapy for Pancreatic Cancer: The Prognostic Significance of Major Pathologic Response

By MedXY|Mar 28, 2026

This review evaluates the prognostic value of Major Pathologic Response (MPR) in pancreatic ductal adenocarcinoma, analyzing its impact on survival and its potential to guide personalized adjuvant treatment strategies.

Survival Unaffected by Surgical Complications in Advanced Esophageal Cancer: A JCOG1109 Exploratory Analysis

General SurgeryEsophagectomyJCOG1109

Survival Unaffected by Surgical Complications in Advanced Esophageal Cancer: A JCOG1109 Exploratory Analysis

By MedXY|Mar 15, 2026

This exploratory analysis of the Phase III JCOG1109 trial suggests that postoperative complications do not significantly impair long-term survival in patients receiving intensive neoadjuvant therapy for esophageal cancer, particularly when

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

Gastroenterologyneoadjuvant therapyPancreatic Cancer

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

By MedXY|Mar 2, 2026

The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefi

Neoadjuvant Lenvatinib Plus Pembrolizumab Achieves Robust Pathological Complete Response in Resectable Merkel Cell Carcinoma

Dermatologyimmunotherapylenvatinib

Neoadjuvant Lenvatinib Plus Pembrolizumab Achieves Robust Pathological Complete Response in Resectable Merkel Cell Carcinoma

By MedXY|Jan 19, 2026

A Phase II trial demonstrates that combining lenvatinib with pembrolizumab prior to surgery in Merkel cell carcinoma results in a 57.7% pathological complete response rate, suggesting a highly effective new strategy for managing resectable

Triple-Combination Breakthrough: Penpulimab, Anlotinib, and Chemotherapy Set New Standards for Resectable NSCLC

newsanlotinibneoadjuvant therapy

Triple-Combination Breakthrough: Penpulimab, Anlotinib, and Chemotherapy Set New Standards for Resectable NSCLC

By MedXY|Jan 19, 2026

The ALTER-L043 trial reveals that combining penpulimab, anlotinib, and chemotherapy achieves a staggering 76% major pathologic response rate in resectable non-small cell lung cancer, signaling a potential shift in neoadjuvant treatment para

Personalizing Neoadjuvant Intensity: 5-Year CinClare Data Validate UGT1A1-Guided Irinotecan for Rectal Cancer

GastroenterologyIrinotecanneoadjuvant therapy

Personalizing Neoadjuvant Intensity: 5-Year CinClare Data Validate UGT1A1-Guided Irinotecan for Rectal Cancer

By MedXY|Jan 14, 2026

The 5-year update of the CinClare trial demonstrates that adding irinotecan to neoadjuvant chemoradiotherapy, guided by UGT1A1 genotype, significantly improves long-term survival and disease-free outcomes in patients with locally advanced r

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results

Gastroenterologyimmunotherapyneoadjuvant therapy

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results

By MedXY|Jan 13, 2026

A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insight

Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?

newsabemaciclibbreast cancer

Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?

By MedXY|Jan 11, 2026

The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower

Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer

newshead and neck cancerneoadjuvant therapy

Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer

By MedXY|Jan 11, 2026

This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial

newsfinancial toxicityimmunotherapy

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial

By MedXY|Jan 8, 2026

The PLANeT trial demonstrates that low-dose pembrolizumab (50 mg) plus chemotherapy significantly improves pathological complete response rates in triple-negative breast cancer, offering a high-efficacy, cost-effective alternative for resou

Disitamab Vedotin Plus Gemcitabine Shows Promise as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

newsHER2-positiveneoadjuvant therapy

Disitamab Vedotin Plus Gemcitabine Shows Promise as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

By MedXY|Dec 17, 2025

A phase 2 trial reports notable pCR rates and manageable toxicity for Disitamab Vedotin plus gemcitabine in HER2-positive MIBC patients.

Neoadjuvant TQB2102 (Bispecific HER2-Directed ADC) Produces High Pathologic Complete Response Rates in Early and Locally Advanced HER2-Positive Breast Cancer

newsAntibody-drug conjugateneoadjuvant therapy

Neoadjuvant TQB2102 (Bispecific HER2-Directed ADC) Produces High Pathologic Complete Response Rates in Early and Locally Advanced HER2-Positive Breast Cancer

By MedXY|Dec 8, 2025

A randomized phase II trial of the bispecific HER2-directed ADC TQB2102 (n=104) showed robust total pathologic complete response rates (tpCR 57.7–76.9% across cohorts) with manageable grade ≥3 toxicity and no treatment‑related deaths, suppo

Neoadjuvant TAR-200 (intravesical gemcitabine) plus cetrelimab shows improved pathologic responses and MRD signal utility in cisplatin-ineligible MIBC: Primary SunRISe-4 analysis

newsmuscle-invasive bladder cancerneoadjuvant therapy

Neoadjuvant TAR-200 (intravesical gemcitabine) plus cetrelimab shows improved pathologic responses and MRD signal utility in cisplatin-ineligible MIBC: Primary SunRISe-4 analysis

By MedXY|Dec 8, 2025

SunRISe-4 reports higher pCR, pOR, and 1‑year RFS for neoadjuvant TAR‑200 plus cetrelimab versus cetrelimab alone in cisplatin‑ineligible/refusing MIBC, with urinary and circulating tumor DNA MRD correlating with outcomes.

Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05

newsChidamideHDAC inhibitor

Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05

By MedXY|Nov 24, 2025

In a multicentre phase 2 single-arm trial, oral chidamide added to standard epirubicin–cyclophosphamide followed by docetaxel produced an RCB 0–I rate of 35.2% in stage II–III HR+/HER2– breast cancer, with high rates of grade 3–4 neutropeni

Preoperative Single‑Fraction Ablative Radiotherapy for Early HR+ Breast Cancer: Low Toxicity, High Pathologic Responses with Delayed Surgery

newsbreast cancerneoadjuvant therapy

Preoperative Single‑Fraction Ablative Radiotherapy for Early HR+ Breast Cancer: Low Toxicity, High Pathologic Responses with Delayed Surgery

By MedXY|Nov 19, 2025

A phase 1 trial reports tolerable single‑fraction preoperative stereotactic partial‑breast irradiation (30–38 Gy) with low toxicity, preserved cosmesis, and high pathologic complete response rates when surgery was delayed beyond ~9 months o

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis

Clinical Updatesimmunotherapyneoadjuvant therapy

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis

By MedXY|Oct 23, 2025

Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients in

Neoadjuvant FOLFIRINOX versus Gemcitabine-Based Chemoradiotherapy in Resectable and Borderline Resectable Pancreatic Cancer: Insights from the PREOPANC-2 Phase 3 Trial

General SurgerychemoradiotherapyFOLFIRINOX

Neoadjuvant FOLFIRINOX versus Gemcitabine-Based Chemoradiotherapy in Resectable and Borderline Resectable Pancreatic Cancer: Insights from the PREOPANC-2 Phase 3 Trial

By MedXY|Oct 15, 2025

The PREOPANC-2 trial compared neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer, finding no significant overall survival difference between the two regimens.

Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC: Advancing Preoperative Therapeutics

Clinical UpdatesEGFR-mutated NSCLCneoadjuvant therapy

Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC: Advancing Preoperative Therapeutics

By MedXY|Oct 6, 2025

Neoadjuvant osimertinib, alone or with chemotherapy, significantly improves major pathological response rates in resectable EGFR-mutated NSCLC, offering a promising approach to enhance surgical outcomes and event-free survival with an accep

Ask MedXY AI

Most popular

Intimate Health

Five Benefits for Women Continuing Sexual Activity After Menopause

Intimate Health

Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

How often should a couple have sex?

Intimate Health

Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Intimate Health

What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities